Transient lymphocyte count decrease correlates with oncolytic adenovirus efficacy in humans: mechanistic and biomarker findings from TUNIMO phase I trial
Journal for ImmunoTherapy of Cancer · 2025-01 · 13 (1) · e010493
DOI: 10.1136/jitc-2024-010493 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 27.01.2025. Verfasst von Santeri A Pakola und 18 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland. Hauptthemen laut MEDLINE: Oncolytic Virotherapy, Oncolytic Viruses, Neoplasms, Adenoviridae. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Karl Fazer, TILT Biotherapeutics, HORIZON EUROPE Marie Sklodowska-Curie Actions.
Abstract (Originalsprache)
Background
Oncolytic viruses (OVs) are promising immunotherapeutics to treat immunologically cold tumors. However, research on the mechanism of action of OVs in humans and clinically relevant biomarkers is still sparse. To induce strong T-cell responses against solid tumors, TILT-123 (Ad5/3-E2F-d24-hTNFa-IRES-hIL2, igrelimogene litadenorepvec) was developed. TILT-123 encodes two transgenes: tumor necrosis alpha (TNFa) and interleukin-2 (IL-2). TUNIMO ( NCT04695327 ) was a phase I clinical trial using TILT-123 in patients with advanced solid tumors aiming to assess the safety, efficacy, and immunological effects of TILT-123. Research presented in this study evaluated the immunological effects of TILT-123 in the TUNIMO trial by using biological samples collected from the patients during the study, with an objective to leverage the findings to develop possible biomarkers of response and gain insights into possible synergistic combination treatments.
Methods
20 patients with advanced solid tumors were treated with TILT-123. Response to therapy was assessed with contrast-enhanced CT and fluorodeoxyglucose positron emission tomography, along with overall survival (OS) calculation. Biological samples from patients were collected in the form of blood and tumor biopsies. Collected samples were analyzed with immunohistochemistry, transcriptomics, proteomics, and flow cytometry.
Results
TILT-123 induced cyclical decreases in blood lymphocyte count, and more substantial blood lymphocyte count correlated with better radiographical response and longer OS. Lymphocyte count findings were confirmed with external control dataset of 96 patients. More substantial lymphocyte count change was linked to stronger immune activation in plasma proteome after intravenous TILT-123 and the presence of TILT-123 mRNA in tumors. Regarding other assays. tumor biopsies profiled showed increased amounts of CD8+ T cells, CD4+ T cells and NK cells after intravenous TILT-123, but not after intratumoral TILT-123. Transcriptional differences were seen in tumors after intravenous therapy and intratumoral therapy, with patients benefitting therapy showing stronger downregulation of immune activation at all time points.
Conclusions
TILT-123 therapy induced accumulation of effector lymphocytes in tumors. Peripheral lymphocyte count decrease is a promising biomarker for assessing oncolytic adenovirus therapy response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.
- TILT Biotherapeutics Ltd, Helsinki, Finland.
- Comprehensive Cancer Center, HUS Helsinki University Hospital, Helsinki, Finland.
- Docrates Cancer Center, Helsinki, Finland.
- Digital Microscopy and Molecular Pathology Unit, University of Helsinki Institute for Molecular Medicine, Helsinki, Finland.
- Health and Hospital Services, Wellbeing Services County of North Karelia - Siun sote, Joensuu, Finland.
Förderung
- Karl Fazer
- TILT Biotherapeutics
- HORIZON EUROPE Marie Sklodowska-Curie Actions
- HORIZON EUROPE Framework Programme
- Doctoral Programme of Clinical Research
- Syöpäsäätiö
- Jane ja Aatos Erkon Säätiö
- HUCH Research Funds
Zitieren
APA
Pakola, S. A., Clubb, J. H. A., Kudling, T. V., van der Heijden, M., Jirovec, E., Arias, V., Haybout, L., Peltola, K., Alanko, T., Sormunen, J., Pellinen, T., Taipale, K., Quixabeira, D. C. A., Kistler, C., Havunen, R., Sorsa, S., Santos, J. M., Cervera-Carrascon, V., & Hemminki, A. (2025). Transient lymphocyte count decrease correlates with oncolytic adenovirus efficacy in humans: mechanistic and biomarker findings from TUNIMO phase I trial. Journal for ImmunoTherapy of Cancer, 13(1), e010493. https://doi.org/10.1136/jitc-2024-010493
Vancouver
Pakola SA, Clubb JHA, Kudling TV, van der Heijden M, Jirovec E, Arias V, et al. Transient lymphocyte count decrease correlates with oncolytic adenovirus efficacy in humans: mechanistic and biomarker findings from TUNIMO phase I trial. Journal for ImmunoTherapy of Cancer. 2025;13(1):e010493. doi:10.1136/jitc-2024-010493
BibTeX
@article{Pakola2025,
author = {Pakola, Santeri A and Clubb, James H A and Kudling, Tatiana V and van der Heijden, Mirte and Jirovec, Elise and Arias, Victor and Haybout, Lyna and Peltola, Katriina and Alanko, Tuomo and Sormunen, Jorma and Pellinen, Teijo and Taipale, Kristian and Quixabeira, Dafne C A and Kistler, Claudia and Havunen, Riikka and Sorsa, Suvi and Santos, Joao M and Cervera-Carrascon, Victor and Hemminki, Akseli},
title = {Transient lymphocyte count decrease correlates with oncolytic adenovirus efficacy in humans: mechanistic and biomarker findings from TUNIMO phase I trial},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2025},
volume = {13},
number = {1},
pages = {e010493},
doi = {10.1136/jitc-2024-010493}
}
EUVIMED